AbbVie (NYSE:ABBV) traded with a cut of -0.12 points or -0.2% at $59.99 per share. As per the last available information, the stock aggregated $64.68 million in upticks and $49.23 million in downticks, keeping the net money flow capped at $15.46 million. The up/down ratio was found to be 1.31. For the week, the shares have seen a change of -0.03% in the share price.A block trade of $21.09 million in upticks and $9.34 million in downticks also took place during the day. The up/down ratio for the block stood at 2.26. The net money flow for this transaction was $11.74 million.
The stock has recorded a 20-day Moving Average of 2.66% and the 50-Day Moving Average is 2.05%. The company shares have dropped 14.15% in the past 52 Weeks. On July 21, 2015 The shares registered one year high of $71.6 and one year low was seen on October 22, 2015 at $45.45. The 50-day moving average is $61.67 and the 200 day moving average is recorded at $58.1. S&P 500 has rallied 1.93% during the last 52-weeks.
AbbVie (NYSE:ABBV): The stock opened at $60.20 on Tuesday but the bulls could not build on the opening and the stock topped out at $60.40 for the day. The stock traded down to $59.75 during the day, due to lack of any buying support eventually closed down at $59.98 with a loss of -0.22% for the day. The stock had closed at $60.11 on the previous day. The total traded volume was 6,366,529 shares.
Currently the company Insiders own 0.11% of AbbVie shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -16.87% . Institutional Investors own 66.78% of AbbVie shares. During last six month period, the net percent change held by insiders has seen a change of -14.58%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Gonzalez Richard A, director officer (Chairman of the Board and CEO) of Abbvie Inc., had unloaded 285,953 shares at an average price of $63.87 in a transaction dated on June 2, 2016. The total value of the transaction was worth $18,263,818.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.